Physician profile
Bryan Blare
NPI 1063409548
$3,749.97
in general payments reported to CMS, 2019-2025
23 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $747 · 2020: $318 · 2021: $317 · 2022: $904 · 2023: $624 · 2024: $546 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,462.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $775.74 | 2019-2022 | |
| Glaukos Corporation | $318.54 | 2020-2022 | |
| Harrow Eye, LLC | $308.12 | 2023-2025 | Iheezo, Vevye, Verkazia |
| Bausch & Lomb Americas INC. | $298.93 | 2023-2025 | Infuse, Biotrue One Day, Miebo |
| Alcon Vision LLC | $268.91 | 2019-2022 | |
| Biotissue Holdings INC. | $252.32 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $234.03 | 2019-2025 | |
| Tarsus Pharmaceuticals, INC. | $218.90 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $201.98 | 2022-2023 | Omni Surgical System |
| Notal Vision, INC. | $149.76 | 2022 | |
| Novartis Pharmaceuticals Corporation | $142.51 | 2022-2023 | |
| Johnson & Johnson Vision Care, INC. | $120.82 | 2019 | |
| Shire North American Group INC | $118.87 | 2019 | |
| Dompe US, INC. | $95.08 | 2024-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $50.69 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $45.56 | 2023-2024 | Tyrvaya, Ryzumvi |
| Thea Pharma INC. | $33.79 | 2023-2024 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.74 | 2020 | |
| Tearlab Corp | $21.18 | 2024 | Scoutpro Osmolarity System |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Abbvie INC. | $18.86 | 2024 | |
| Eyevance Pharmaceuticals LLC | $17.21 | 2022 | |
| Amgen INC. | $17.03 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Blare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.